

Omeprazole | Esomeprazole

Selected References:

- Ali, R, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. *BMC gastroenterology*; 22.1: 1-10.
- Anderka M, et al. 2012. National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol*; 94:22-30.
- Andersen ABT, et al. 2012. Prenatal exposure to acid-suppressive drugs and the risk of toddler asthma: a population-based Danish cohort study. *Alim Pharmacol Ther*; 35:1190-1198.
- Anderson P. 2018. Treating gastroesophageal reflux and heartburn while breastfeeding. *Breastfeed Med*;13(7):463-4.
- Bank, T, et al. 2024. Challenges in Conducting Clinical Trials for Preeclampsia. *Curr Hypertens Rep* 26, 59-68.
- Bor S, et al. 2017. The levels of pantoprazole in human breast milk and plasma: two compartment model. *Neurogastroenterol Motil*; 29:79-80.
- Dehlink E, et al. 2009. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. *Clin Exp Allergy* 39:246-53.
- Diav-Citrin O, et al. 2005. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. *Aliment Pharmacol Ther*; 21:269-75.
- Erichsen R, et al. 2014. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. *Am J Ther*; 21: 254-259.
- Gill SK et al. 2009. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. *Am J Gastroenterol*; 104(6): 1541-1545.
- Hastie R, et al. 2019. Proton pump inhibitors and preeclampsia risk among 157 720 women: a Swedish population register-based cohort study. *Hypertension*; 73(5):1097-103.
- Huijgen NA. 2016. Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy? *Fertility and Sterility*, 106(7), 1666-1672.
- Kallen B. 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. *Br J Obstet Gynaecol*; 105:877-881.
- Kallen B. 2001. Use of omeprazole during pregnancy—no hazard demonstrated in 955 infants exposed during pregnancy. *Eur J Obstet Gynecol Reprod Biol*; 96:63-68.
- Keihani, S. et al. 2018. Proton-pump inhibitor use does not affect semen quality in subfertile men. *Asian journal of andrology*, 20(3), 290.
- Lalkin A, et al. 1998. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. *Am J Obstet Gynecol*; 179(3 Pt 1): 727-730.
- Li, C, et al. 2020. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy. *Alimentary pharmacology & therapeutics*; 51.4: 410-420.
- Mahadevan, Uma. 2007. "Gastrointestinal Medications in Pregnancy." *Best Practice & Research Clinical Gastroenterology* 21(5): 849-77.
- Majithia, R., & Johnson, D. A. (2012). Are Proton Pump Inhibitors Safe during Pregnancy and Lactation? 10.
- Marshall JK, et al. 1998. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. *Can J Gastroenterol*; 12: 225-227.
- Matok I, et al. 2012. The safety of fetal exposure to proton-pump inhibitors during pregnancy. *Dig Dis Sci*; 57:699-705.
- Mumtaz, N, et al. Harmful Consequences of Proton Pump Inhibitors on Male Fertility: An Evidence from Subchronic Toxicity Study of Esomeprazole and Lansoprazole in Wistar Rats. *International Journal of Endocrinology*.

- Nikfar S, et al. 2002. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. *Dig Dis Sci*; 47:1526-9.
- Neuman R, et al. 2022. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1). *Hypertension*, vol. 79,6: 1297-1307.
- Pasternak B, Hviid A. 2010. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. *N Engl J Med*; 363:2114-2123.
- Saito J, et al. 2020. Esomeprazole During Pregnancy and Lactation: Esomeprazole Levels in Maternal Serum, Cord Blood, Breast Milk, and the Infant's Serum. *Breastfeeding Medicine*, bfm.2020.0175.
- Thélin CS, & Richter JE. 2020. Review article: the management of heartburn during pregnancy and lactation. *Alimentary Pharmacology & Therapeutics*, 51(4), 421-434.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. *J Clin Pharmacol*; 56: 116-123

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Omeprazole | Esomeprazole

Selected References:

- Affendi Raja RA, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. *BMC Gastroenterology*, 22:219-229.
- Courtney TP, et al. 1988. Excretion of famotidine in breast milk. *Br J Clin Pharmacol*, 626:639P.
- Garbis H, et al. 2005. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. *Reprod Toxicol*, 19:453-458.
- Hagemann, TM, 1998. Gastrointestinal medications and breastfeeding. *Journal of Human Lactation*, 14(3):259-262.
- Kallen B, 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special

reference to omeprazole. Journal of Obstetrics and Gynecology, 105:877-881.

- Magee LA, et al. 1996. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci, 41(6):1145-1149.
- Matok I, et al. 2010. The safety of H (2)-blockers use during pregnancy. J Clin Pharmacol, 50(1):81-87.
- Orenstein SR, Shalaby TM, Devandry SN, et al. 2003. Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther, 7(9):1097-107.
- Savarino V, et al. 1988. Famotidine has no significant effect on gonadal function in man. Gastroenterol Clin Biol, 12:19-22.
- Wang X, et al. 2011. Pharmacokinetics of famotidine in pregnant women. Am J Obstet Gynecol., 204: 72-73.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. J Clin Pharmacol, 56(1):116-123.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Omeprazole | Esomeprazole

Selected References:

- Barrau M, et al. 2023. What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?. J Clin Med. 12(23):7495.
- Bell C, et al. 2021. Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. J Gastroenterol Hepatol;36(10):2640-2648. PMID: 34110640 DOI: 10.1111/jgh.15574
- Caballero-Mateos AM, et al. 2023. IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond. J Clin Med. 12(19):6192.
- Chugh R. 2023. Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results from the PIANO registry. Am J Gastroenterol. DOI: 10.14309/ajg.0000000000002553.
- Ding N, et al. 2022. Management of biologics in pregnant, lactating patients with inflammatory bowel disease

and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements. *J Clin Pharm Ther.* 47(12):1952-1965.

- Gisbert JP, et al. 2023. Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?. *J Crohns Colitis.* 17 (6):995-1009.
- Gisbert JP, et al. 2020. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. *Drugs*;80(11):1085-1100. PMID: 32562207 DOI: 10.1007/s40265-020-01346-4
- Honap S, et al. 2023. An update on the safety of long-term vedolizumab use in inflammatory bowel disease. *Expert Opin Drug Saf.* 22 (9):767-776.
- Julsgaard M, et al. 2017. Vedolizumab safety in pregnancy and newborn outcomes. *Gut*; 66(10):1866-1867.
- Julsgaard M, et al. 2018. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. *Gastroenterology* 154: 752-765.
- Lahat A, et al. 2018. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. *J Crohns Colitis*; 12:120-3.
- Lamb CA, et al. 2019. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* ;68(Suppl 3):s1-s106. PMID: 31562236 PMCID: PMC6872448 DOI: 10.1136/gutjnl-2019-318484
- Laube R, et al. 2021. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. *Expert Opin Drug Saf* ;20(3):275-292. PMID: 33412078 DOI: 10.1080/14740338.2021.1873948
- Mahadevan U, et al. 2017. Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease. *Aliment Pharmacol Ther*; 45:941-950.
- Mahadevan U, et al. 2017. Editorial: vedolizumab in pregnancy – is gut selectivity as good for baby as it is for mum? Authors' reply. *Aliment Pharmacol Ther.* 45(9):1284.
- Meyer A, et al. 2024. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol.* DOI: 10.1016/j.cgh.2023.12.029.
- Mitrova K, et al. 2022. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. *Journal of Crohn's & colitis.* Vol 16, 12: 1808-1815.
- Moens A, et al. 2019. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. *J Crohns Colitis* 13(1): 12-13.
- Moens A, et al. 2020. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. *Aliment Pharmacol Ther* 51(1): 129-138.
- Nielsen OH. 2022. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol.* 20(1):74-87.
- Pugliese D, et al. 2024. New drugs for the treatment of IBD during conception, pregnancy, and lactation. *Dig Liver Dis.* 56 (2): 235-241.
- Rosario M, et al. 2017. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. *Clin Pharmacokinet.* 2017; 56(11): 1287-1301. PMCID: PMC5648740 PMID: 28523450
- Sheridan J, et al. 2017. Letter: Vedolizumab in Pregnancy. *J Crohns Colitis*; 11(8):1025-1026.
- Shitrit AB-G A, et al. 2019. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: A first perspective comparison study. *Am J Gastroenterol* 114(7): 1172-1175.
- Sun W, et al. 2021. Vedolizumab concentrations in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease. *Clin Pharmacokinet.* 60:811-8.
- Takeda Pharmaceuticals America, Inc. 2018. Entyvio product label. Available at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c>

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Omeprazole | Esomeprazole

Selected References:

- Andrade C. 2020. Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron. *J Clin Psychiatry*;81(3):20f13472
- Anderka M, et al. 2012. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol*; 94(1):22-30.
- Briggs GG, Freeman RK. 2014. *Drugs in Pregnancy and Lactation*. 10th edition. Philadelphia, PA: Wolters Kluwer (online version).
- Kaplan YC, et al. 2019. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systemic review and meta-analysis. *Reprod Toxicol*; 86 Jun:1-13.
- Cao X, et al. 2022. Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis. *Front Pharmacol*, 13(951072).
- Cohen R, et al. 2014. Intestinal obstruction in pregnancy by ondansetron. *Reprod Toxicol*. 2014 Oct 24;50C:152-153.
- Colvin L, et al. 2013. Off-label use of ondansetron in pregnancy in Western Australia. *Biomed Res Int*. 2013:909860.
- Danielsson B, Wikner BN, Kallen B. 2014. Use of ondansetron during pregnancy and congenital malformations in the infant. *Reprod Toxicol* 50:134-7.
- Diav-Citrin O, et al. 2017. Pregnancy outcome following in utero exposure to ondansetron: A prospective comparative, observational cohort study. *Reprod Toxicol*; 72:203.
- Dormuth CR, et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. 2021. Comparison of Pregnancy Outcomes of Patients Treated with Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. *JAMA Netw Open*; 4(4):e215329.
- Einarson AK, et al. 2004. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. *BJOG*;111:940-3.
- Elkomy MH, et al. 2015. Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. *Clin Pharmacol Ther*. 97:167-76.
- Fejzo MS, et al. 2016. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. *Reprod Toxicol* 62: 87-91.

- Food and Drug Administration. 2012. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran>. Accessed 2018 & 2022.
- Jelting Y, et al. 2017. Preventing nausea and vomiting in women undergoing regional anesthesia for cesarean section: Challenges and solutions. *Local Reg Anesth*, 10:83-90.
- Larrimer MB, et al. 2014. Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. *Am J Obstet Gynecol* 210 (3): 270. e1-7
- Lavecchia M, et al. 2018. Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review. *J Obstet Gynaecol Can.* 40(7):910-918.
- Lemon LS, et al. 2020. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. *Int J Epidemiol*;49(2):648-656.
- Masarwe S, et al. 2023. Ondansetron use during pregnancy: Birth defects and obstetric outcomes. *Clin Nurs Res*, 32(4):705-711.
- Pasternak B. 2013. Ondansetron in pregnancy and risk of adverse fetal outcomes. *N Engl J Med* 368:814-823.
- Picot C, et al. 2020. Risk of malformation after ondansetron in pregnancy: An updated systemic review and meta-analysis. *Birth Defects Res*;112(13):996-1013.
- Reis ACC, et al. 2023. Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats. *Regul Toxicol Pharmacol*, 137:105302.
- Sakran R, et al. 2021. Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. *Reprod Toxicol*; 99:9-14.
- Schrager NL, et al. 2023. The association of nausea and vomiting of pregnancy, its treatments, and select birth defects: Findings from the National Birth Defect Prevention Study. *Birth Defects Res*, 115(3):275-289.
- Suarez EA, et al. 2021. Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. *Pharmacoepidemiol Drug Saf*; 30(2):114-125.
- Suarez EA, et al. 2021. Ondansetron use in early pregnancy and the risk of miscarriage. *Pharmacoepidemiol Drug Saf*; 30(2):103-113.
- Zhao W, et al. 2020. Retrospective comparison of the safety and effectiveness of dexmedetomidine versus standard of care before and during cesarean delivery in a maternity unit in Zhengzhou, China. *Med Sci Monit*, 26:e925709.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Omeprazole | Esomeprazole

Selected References:

- Andersen, J. B, et al. 2023. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. *European journal of neurology*, 30(1), 162-171.
- Ciplea, A. I, et al. 2020. Exposure to natalizumab during pregnancy and lactation is safe – Commentary. *Multiple sclerosis (Houndmills, Basingstoke, England)*, 26(8), 892-893.
- D’Amico, E, et al. 2021. Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. *Multiple sclerosis (Houndmills, Basingstoke, England)*, 27(14), 2284-2287.
- Ebrahimi N, et al. 2014. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. *Mult Scler*. 2015 Feb;21(2):198-205.
- Friend S, et al. 2016. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. *BMC Neurol*. Aug 24;16(1):150
- Gklinos, P, et al. 2023. Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide. *Pharmaceuticals (Basel, Switzerland)*, 16(5), 770.
- Haghighi A, , et al. 2014. Natalizumab use during the third trimester of pregnancy. *JAMA Neurol* 71(7): 891-895.
- Mahadevan U, , et al. 2019. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. *Gastroenterology*. Apr;156(5):1508-1524.
- Massarotti, C., et al. 2021. Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. *Journal of clinical medicine*, 10(22), 5401
- O’Leary, S, et al. 2023. Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis. *Journal of infusion nursing : the official publication of the Infusion Nurses Society*, 46(6), 347-359.
- Oreja-Guevara, C, et al. 2023. Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements. *Cureus*, 15(8), e44056
- Peng A, et al. 2018. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. *J Neurol Sci*. 2019 Jan 15;396:202-205.
- Portaccio E, et al. 2018. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. I: Fetal risks. *Neurology*. Page #s or journal volume?
- Simone, I. L, et al. 2021. Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies. *Frontiers in neurology*, 12, 697974.
- Tysabri. Drug Approval Package. Pharmacology reviews. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_natalizumab.cfm
- Ramesh, V, et al. 2022. Adverse Obstetric Outcomes in Pregnant Women Using Natalizumab for the Treatment of Multiple Sclerosis: A Systematic Review. *Cureus*, 14(10), e29952

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.